Search - tctmd.com

Displaying 461 - 480 of 783

Sort: Relevancy | Date

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

News Conference News ESC 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

August 26, 2017

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

News Conference News SCCT 2017

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Yael L. Maxwell

July 13, 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

June 02, 2017

EUROCTO: Revascularization Bests Medical Therapy for Quality of Life in CTO Lesions

News Conference News EuroPCR 2017

EUROCTO: Revascularization Bests Medical Therapy for Quality of Life in CTO Lesions

Yael L. Maxwell

May 18, 2017

FFR-SEARCH Explores Potential of Physiologic Assessment After PCI

News Conference News EuroPCR 2017

FFR-SEARCH Explores Potential of Physiologic Assessment After PCI

May 18, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

iFR and FFR Equally Safe for Deferring Revascularization, Pooled Analysis Shows

News Conference News EuroPCR 2017

iFR and FFR Equally Safe for Deferring Revascularization, Pooled Analysis Shows

May 16, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

CMR Perfusion Imaging Holds Its Own Against Invasive Approach to Managing Stable Angina

News Conference News ACC 2017

CMR Perfusion Imaging Holds Its Own Against Invasive Approach to Managing Stable Angina

March 22, 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

News Conference News ACC 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

Yael L. Maxwell

March 19, 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

News Conference News ACC 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

March 18, 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

March 18, 2017

Live From Washington: ACC 2017, Day Two

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

March 18, 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

Live From Washington: ACC 2017, Day One

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

March 17, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

To Stent or Not to Stent? iFR vs FFR Late Breakers at ACC 2017 Seek to Shake Up Treatment Decisions

News Conference News ACC 2017

To Stent or Not to Stent? iFR vs FFR Late Breakers at ACC 2017 Seek to Shake Up Treatment Decisions

March 14, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.